| Targeting colon cancer with the novel STAT3 inhibitor bruceantinol N Wei, J Li, C Fang, J Chang, V Xirou, NK Syrigos, BJ Marks, E Chu, ... Oncogene 38 (10), 1676-1687, 2019 | 78 | 2019 |
| CD24: a novel target for cancer immunotherapy E Panagiotou, NK Syrigos, A Charpidou, E Kotteas, IA Vathiotis Journal of Personalized Medicine 12 (8), 1235, 2022 | 47 | 2022 |
| Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials E Panagiotou, G Gomatou, IP Trontzas, N Syrigos, E Kotteas Clinical and Translational Oncology 24 (2), 161-192, 2022 | 41 | 2022 |
| Tumor dormancy: implications for invasion and metastasis G Gomatou, N Syrigos, IA Vathiotis, EA Kotteas International journal of molecular sciences 22 (9), 4862, 2021 | 34 | 2021 |
| Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it M Drizou, EA Kotteas, N Syrigos Clinical and Translational Oncology 19, 658-666, 2017 | 32 | 2017 |
| Osimertinib resistance: molecular mechanisms and emerging treatment options G Gomatou, N Syrigos, E Kotteas Cancers 15 (3), 841, 2023 | 27 | 2023 |
| Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors G Gomatou, I Trontzas, S Ioannou, M Drizou, N Syrigos, E Kotteas Molecular biology reports 48, 915-925, 2021 | 26 | 2021 |
| Malignant superior vena cava syndrome: state of the art V Patriarcheas, M Grammoustianou, N Ptohis, I Thanou, M Kostis, ... Cureus 14 (1), 2022 | 22 | 2022 |
| The role of kisspeptin system in cancer biology M Stathaki, ME Stamatiou, G Magioris, S Simantiris, N Syrigos, S Dourakis, ... Critical reviews in oncology/hematology 142, 130-140, 2019 | 22 | 2019 |
| Orbital metastases of invasive lobular breast carcinoma IM Tsagkaraki, CD Kourouniotis, GL Gomatou, NK Syrigos, EA Kotteas Breast Disease 38 (3-4), 85-91, 2019 | 20 | 2019 |
| Significant increase in blood pressure following BNT162b2 mRNA COVID-19 vaccination among healthcare workers: a rare event N Syrigos, A Kollias, D Grapsa, E Fyta, KG Kyriakoulis, I Vathiotis, ... Vaccines 10 (5), 745, 2022 | 12 | 2022 |
| Erlotinib-associated rash in advanced non-small cell lung cancer: relation to clinicopathological characteristics, treatment response, and survival I Kainis, N Syrigos, A Kopitopoulou, I Gkiozos, E Filiou, V Nikolaou, ... Oncology Research 26 (1), 59, 2018 | 12 | 2018 |
| Programmed death-ligand 1 as a regulator of tumor progression and metastasis IA Vathiotis, G Gomatou, DJ Stravopodis, N Syrigos International Journal of Molecular Sciences 22 (10), 5383, 2021 | 11 | 2021 |
| Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria N Syrigos, D Grapsa, M Zande, M Tziotou, E Syrigou International Journal of Dermatology 57 (4), 417-422, 2018 | 11 | 2018 |
| Pulmonary blastoma: a comprehensive overview of a rare entity I Tsamis, SP Chachali, G Gomatou, I Trontzas, M Mitsogianni, N Syrigos, ... Advances in Respiratory Medicine 89 (5), 511-519, 2021 | 9 | 2021 |
| Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors MI Toki, N Syrigos, K Syrigos International Journal of Cancer 149 (2), 277-286, 2021 | 9 | 2021 |
| Anticoagulation therapy in COVID-19: Is there a dose-dependent benefit? A Kollias, KG Kyriakoulis, NK Syrigos, GS Stergiou Thrombosis Research 199, 19, 2021 | 9 | 2021 |
| New insights into SARS-CoV-2 and cancer cross-talk: Does a novel oncogenesis driver emerge? V Rapti, T Tsaganos, IA Vathiotis, NK Syrigos, P Li, G Poulakou Vaccines 10 (10), 1607, 2022 | 8 | 2022 |
| Assessment of seroconversion after SARS-CoV-2 vaccination in patients with lung cancer IP Trontzas, I Vathiotis, C Economidou, I Petridou, G Gomatou, ... Vaccines 10 (4), 618, 2022 | 8 | 2022 |
| The role of decoy receptor DcR3 in gastrointestinal malignancy S Lagou, D Grapsa, N Syrigos, G Bamias Cancer Diagnosis & Prognosis 2 (4), 411, 2022 | 7 | 2022 |
